This page shows the latest idebenone news and features for those working in and with pharma, biotech and healthcare.
Other therapeutic approaches under test for DMD include gene-editing with CRISPR/Cas9, myostatin inhibitors from Pfizer, Bristol-Myers Squibb and Biogen/AliveGen, and Santhera’s antioxidant idebenone, which like
These include the use of CRISPR/Cas9, myostatin Inhibitior candidates from Pfizer and BMS, and Santhera which is developing Idebenone (Raxone).
European regulatory advisers have refused to shift their negative position on Santhera’s Duchenne muscular dystrophy (DMD) drug Raxone (idebenone).
The Swiss biopharma company has failed to convince the FDA to accept an accelerated marketing application for Raxone (idebenone) via the truncated subpart H approval pathway, used to hasten the approval
There has been some good news for European DMD patients this week however after Santhera announced it had filed for approval of Raxone (idebenone) for the treatment of DMD.
And finally the CHMP has recommended Santhera's Raxone (idebenone) for the treatment of visual impairment in patients with Leber's hereditary optic neuropathy. .
More from news
Approximately 3 fully matching, plus 7 partially matching documents found.
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...